Assessment of Ki-67 proliferation index with deep learning in DCIS (ductal carcinoma in situ).
Algorithms
Artificial Intelligence
Biomarkers, Tumor
/ metabolism
Breast Neoplasms
/ classification
Carcinoma, Intraductal, Noninfiltrating
/ classification
Cell Proliferation
Deep Learning
Female
Humans
Image Processing, Computer-Assisted
/ methods
Immunohistochemistry
/ methods
Ki-67 Antigen
/ metabolism
Observer Variation
Reproducibility of Results
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
24 02 2022
24 02 2022
Historique:
received:
11
08
2021
accepted:
31
01
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
17
3
2022
Statut:
epublish
Résumé
The proliferation index (PI) is crucial in histopathologic diagnostics, in particular tumors. It is calculated based on Ki-67 protein expression by immunohistochemistry. PI is routinely evaluated by a visual assessment of the sample by a pathologist. However, this approach is far from ideal due to its poor intra- and interobserver variability and time-consuming. These factors force the community to seek out more precise solutions. Virtual pathology as being increasingly popular in diagnostics, armed with artificial intelligence, may potentially address this issue. The proposed solution calculates the Ki-67 proliferation index by utilizing a deep learning model and fuzzy-set interpretations for hot-spots detection. The obtained region-of-interest is then used to segment relevant cells via classical methods of image processing. The index value is approximated by relating the total surface area occupied by immunopositive cells to the total surface area of relevant cells. The achieved results are compared to the manual calculation of the Ki-67 index made by a domain expert. To increase results reliability, we trained several models in a threefold manner and compared the impact of different hyper-parameters. Our best-proposed method estimates PI with 0.024 mean absolute error, which gives a significant advantage over the current state-of-the-art solution.
Identifiants
pubmed: 35210450
doi: 10.1038/s41598-022-06555-3
pii: 10.1038/s41598-022-06555-3
pmc: PMC8873444
doi:
Substances chimiques
Biomarkers, Tumor
0
Ki-67 Antigen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3166Informations de copyright
© 2022. The Author(s).
Références
BMC Bioinformatics. 2017 Nov 29;18(1):529
pubmed: 29187165
Clin Breast Cancer. 2018 Apr;18(2):157-167.e6
pubmed: 29325859
Ann Oncol. 2013 Sep;24(9):2206-23
pubmed: 23917950
J Natl Cancer Inst. 2011 Nov 16;103(22):1656-64
pubmed: 21960707
Am J Pathol. 2019 May;189(5):946-955
pubmed: 30385094
Sci Rep. 2021 Apr 19;11(1):8489
pubmed: 33875676
Ecancermedicalscience. 2015 Mar 31;9:518
pubmed: 25932042
Indian J Pathol Microbiol. 2017 Apr-Jun;60(2):177-184
pubmed: 28631631
J Surg Oncol. 2016 Oct;114(5):548-556
pubmed: 27439354
Sci Rep. 2017 Jun 12;7(1):3213
pubmed: 28607456
BMC Cancer. 2018 Sep 3;18(1):867
pubmed: 30176814
Anal Quant Cytol Histol. 2001 Aug;23(4):291-9
pubmed: 11531144
Hum Pathol. 2016 Mar;49:114-23
pubmed: 26826418
Anticancer Res. 2016 Aug;36(8):3965-72
pubmed: 27466501
PeerJ. 2014 Jun 19;2:e453
pubmed: 25024921
J Surg Oncol. 2017 Nov;116(6):696-705
pubmed: 28570750
IEEE Trans Med Imaging. 2020 Feb;39(2):534-542
pubmed: 31398111
Breast Cancer Res. 2010;12(4):R56
pubmed: 20663194
Int J Mol Sci. 2018 Dec 07;19(12):
pubmed: 30544617